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1. INTRODUCTION 
1.1. Oral Controlled Release Drug Delivery Systems1, 2: 
 Oral controlled release drug delivery is a drug delivery system that provides 
the continuous oral delivery of drugs at predictable and reproducible kinetics for a 
predetermined period throughout the course of GI transit and also the system that 
target the delivery of a drug to a specific region within the GI tract for either local or 
systemic action.  
 All the pharmaceutical products formulated for systemic delivery via the oral 
route of administration, irrespective of the mode of delivery (immediate, sustained or 
controlled release) and the design of dosage form (solid dispersion or liquid), must be 
developed within the intrinsic characteristics of GI physiology. Therefore the 
scientific framework required for the successful development of oral drug delivery 
systems consists of basic understanding of (i) Physicochemical, pharmacokinetic and 
pharmacodynamic characteristics of the drug (ii) the anatomic and physiologic 
characteristics of the gastrointestinal tract and (iii) physicochemical characteristics 
and the drug delivery mode of the dosage form to be designed.  
The main areas of potential challenge in the development of oral controlled 
drug delivery systems are3, 4: - 
1) Development of a drug delivery system: To develop a viable oral controlled 
release drug delivery system capable of delivering a drug at a therapeutically 
effective rate to a desirable site for duration required for optimal treatment.  
2) Modulation of gastrointestinal transit time: To modulate the GI transit time so 
that the drug delivery system developed can be transported to a target site or to 
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the vicinity of an absorption site and reside there for a prolonged period of 
time to maximize the delivery of a drug dose.  
3) Minimization of hepatic first pass elimination: If the drug to be delivered is 
subjected to extensive hepatic first-pass elimination, preventive measures 
should be devised to either bypass or minimize the extent of hepatic metabolic 
effect.  
    1.2. SCOPE OF THE STUDY: 
       Conventional oral controlled dosage forms suffer from mainly two 
adversities. The short gastric retention time (GRT) and unpredictable gastric 
emptying time (GET). A relatively brief GI transit time of most drug products 
impedes the formulation of single daily dosage forms. Altering the gastric 
emptying can overcome these problems. Therefore it is desirable, to formulate a 
controlled release dosage form that gives an extended GI residence time. 
Extended release dosage form with prolonged residence time in stomach are 
highly desirable for drugs.  
i. That are locally active in stomach,  
ii. That have an absorption window in the stomach or in the upper small 
intestine,  
iii. That are unstable in the intestinal or colonic environment,  
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iv. Have low solubility at high pH values. 
1.3. Gastro retentive Dosage Form (GRDF) 5, 6: 
 It is evident from the recent scientific and patient literature that an increased 
interest in novel dosage forms that are retained in stomach for a prolonged and 
predictable period of time exists today in academic and industrial research groups. 
One of the most feasible approaches for achieving a prolonged and predictable drug 
delivery in the GI tract is to control the gastric residence time (GRT), i.e. gastro 
retentive dosage form (GRDFs or GRDS).  
 GRDFs extend significantly the period of time over which the drugs may be 
released. They not only prolong dosing intervals, but also increase patient compliance 
beyond the level of existing controlled release dosage form.  
Dosage form with prolonged GRT, i.e. gastro retentive dosage form (GRDF), will 
bring about new and important therapeutic options such as –  
1) This application is especially effective in sparingly soluble and insoluble 
drugs, as the solubility of a drug decreases, the time available for drug 
dissolution becomes less adequate and thus the transit time becomes affecting 
drug absorption. To override this problem, erodible, gastro retentive dosage 
forms have been developed that provide continuous, controlled administration 
of sparingly soluble drugs at the absorption site.  
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2) GRDFs greatly improve the pharmacotherapy of the stomach through local 
drug release, leading to high drug concentration at the gastric mucosa. (For 
e.g. Eradicating Helicobacter pylori from the sub mucosal tissue of stomach)  
3) GRDFs can be used as carriers for drugs with so-called absorption windows. 
These substances for e.g. antiviral, antifungal and antibiotic agents are taken 
up only from very specific sites of the GI mucosa. 
1.3.1. PHYSIOLOGY OF GASTRO INTESTINAL TRACT:  
 Physiology of gastro intestinal tract 
 
Fig.No:1. Diagram of Stomach 
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1.3.2. Factors Controlling Gastric Retention Time of Dosage Form6, 7:the gastric 
retention time (GRT) of dosage form is controlled by several factors that affect their 
efficacy as a gastro retentive system.  
 Density of dosage form:  – the density of gastric fluid is reported to be 
1.004g/cm3.The density of the dosage form should be less than this for 
buoyancy, so that it is retained in stomach for longer period of time. The 
dosage form may be having a high density in the beginning, but due to 
reduction in density by swelling it will float in stomach. 
 Size of the dosage from: –studies on the effect of particle size on gastric 
retention have been inconclusive. The non-disintegrating tablets as large as 
7mm can be emptied from human stomach during the post-prandial period, 
while 13mm tablets are retained until arrival of subsequent sweeping 
“housekeeper wave”. This emphasizes the need for size enlargement of DF in 
stomach in order to prolong GRT. 
 Shape of dosage form – Tetrahedron and ring-shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KPSI) are reported to 
have better GRT. 90% to 100% retention at 24 hours compared with other 
shapes. 
 Single or multiple unit formulation – Multiple unit formulations show a 
more predictable release profile and insignificant impairing of performance 
due to failure of units, allow co-administration of units with different release 
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profiles or containing incompatible substances and permit a larger margin of 
safety against dosage form failure compared with single unit dosage forms. 
 Fed or unfed state – Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex 
(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and 
GRT is considerably longer.  
 Nature of meal – Feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release. 
 Caloric content – GRT can be increased by four to 10 hours with a meal that 
is high in proteins and fats.  
 Frequency of feed – The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
 Gender – Mean ambulatory GRT in males (3.40.6 hours) is less compared 
with their age and race-matched female counterparts (4.61.2 hours), 
regardless of the weight, height and body surface. 
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 Age – Elderly people, especially those over 70, have a significantly longer 
GRT. 
 Posture – GRT can vary between supine and upright ambulatory states of the 
patient. Concomitant drug administration – Anticholinergics like Atropine and 
Propantheline, opiates like Codeine and prokinetic agents like 
Metoclopramide and Cisapride. 
BIOLOGICAL ASPECTS OF GRDFs: 
Role of GI tract34: 
Stomach  
 
Fig.No:2.Anatomy of Stomach 
INTRODUCTION 
 
Dept. of Pharmaceutics        8  JKKMMRF College of Pharmacy 
 
 The stomach is J-shaped organ located in the upper left hand portion of the 
abdomen, just below the diaphragm. It occupies a portion of the epigastric and left 
hydrochondriac region. The main function of the stomach is to store the food 
temporarily, grind it and then release it slowly into the duodenum. Due to its small 
surface area very little absorption takes place from the stomach. It provides barrier to 
the delivery of drugs to small intestine.  
The stomach is divided into three anatomical regions. I) Fundus ii) Body and 
iii) Pylorus (or antrum). The proximal stomach consisted of fundus and body, which 
serves as a reservoir for ingested materials, whereas the distal region (pylorus) is the 
major site of mixing motions, acting as a pump to propel gastric contents for gastric 
emptying. Gastric emptying occurs both in fasting as well as fed states. 
The GI tract is always in a state of continuous motility. There are two modes 
of motility pattern. The digestive mode and interdigestive mode. In case of fasted 
state an interdigestive series of electrical events occurs in cyclic manner both through 
stomach and small intestine every 2-3 hr. This electrical activity is termed as 
interdigestive my electric cycle. 
Phase I : Period of no contraction. 
Phase II : Period of intermittent contraction.  
Phase III            :  Period of regular contractions at the maximal frequency that migrate 
distally. 
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Phase III has a housekeeping role and serves to clear all indigestible materials 
from the stomach and small intestine. Consequently, a controlled-release 
gastrointestinal drug delivery system must be capable of resisting the house keeping 
action of phase III. Studies revealed that in the fed state, the gastric emptying rate is 
slowed since the onset of MMC is delayed. It can be concluded that feeding results in 
a lag time before onset of gastric emptying cycle14, 15. 
APPROACHES TO GASTRIC RETENTION35 
Various approaches have been pursued to increase the retention of an oral 
dosage form in the stomach. These systems include: Floating systems, Bio adhesive 
systems, swelling and expanding systems, High density systems, Modified systems                  
Buoyant/ Floating Systems: 
Floating Drug Delivery System (FDDS) have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, 
without affecting the gastric emptying rate. While the system is floating on the gastric 
contents, the drug is released slowly at a desired rate from the system. After the 
release of the drug, the residual system is emptied from the stomach. This results in an 
increase in the GRT and a better control of fluctuations in the plasma drug 
Phase IV : Is the transition period of 0-5 mins between Phase III & I. 
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concentrations. Floating systems can be classified into two distinct categories, non-
effervescent and effervescent systems. 
 
Fig.No:3.Graphic of Buoyant tablet, which is less dense than the stomach fluid 
and therefore remains in the fundus. 
Bio/Muco-adhesive Systems: 
Bio/Muco-adhesive systems are those which bind to the gastric epithelial cell 
surface or mucin and serve as a potential means of extending the GRT of drug 
delivery system in the stomach, by increasing the intimacy and duration of contact of 
drug with the biological membrane.  
The surface epithelial adhesive properties of mucin have been well recognized 
and applied to the development of GRDDS based on bio/muco-adhesive polymers. 
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The ability to provide adhesion of a drug (or a delivery system) to the GI wall 
provides a longer residence time in a particular organ site, thereby producing an 
improved effect in terms of local action or systemic effect. Binding of polymers to the 
mucin/epithelial surface can be divided into three broad categories: – 
1. Hydration-mediated adhesion. 
2. Bonding-mediated adhesion. 
3. Receptor-mediated adhesion. 
 
Swelling and Expanding Systems: 
These are the dosage forms, which after swallowing; swell to an extent that 
prevents their exit from the pylorus. As a result, the dosage form is retained in the 
stomach for a long period of time. These systems may be named as “plug type 
system”, since they exhibit the tendency to remain logged at the pyloric sphincter if 
that exceed a diameter of approximately 12-18 mm in their expanded state. The 
formulation is designed for gastric retention and controlled delivery of the drug into 
the gastric cavity. Such polymeric matrices remain in the gastric cavity for several 
hours even in the fed state. A balance between the extent and duration of swelling is 
maintained by the degree of cross-linking between the polymeric chains. A high 
degree of cross-linking retards the swelling ability of the system maintaining its 
physical integrity for prolonged period. 
High Density Systems: 35 
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These systems with a density of about 3 g/cm3 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 2.6-
2.8 g/cm3 acts as a threshold value after which such systems can be retained in the 
lower part of the stomach. High-density formulations include coated pellets. Coating 
is done by heavy inert material such as barium sulphate, zinc oxide, titanium dioxide, 
iron powder etc. They are retained in the antrum of stomach as shown in Fig. 4. 
  
 
 
Fig.No:4. Graphic of heavy tablet, which is denser than the stomach fluid and 
therefore sinks to the antrum. 
Incorporation of Passage Delaying Food Agents:  
Food excipients like fatty acids e.g. salts of myristic acid change and modify 
the pattern of the stomach to a fed state, thereby decreasing gastric emptying rate and 
permitting considerable prolongation of release. The delay in the gastric emptying 
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after meals rich in fats is largely caused by saturated fatty acids with chain length of 
C10-C14 
Ion Exchange Resins: 
A coated ion exchange resin bead formulation has been shown to have gastric 
retentive properties, which was loaded with bicarbonates. Ion exchange resins are 
loaded with bicarbonate and a negatively charged drug is bound to the resin. The 
resultant beads were then encapsulated in a semi-permeable membrane to overcome 
the rapid loss of carbon dioxide. Upon arrival in the acidic environment of the 
stomach, an exchange of chloride and bicarbonate ions take place. As a result of this 
reaction carbon dioxide was released and trapped in the membrane thereby carrying 
beads towards the top of gastric content and producing a floating layer of resin beads 
in contrast to the uncoated beads, which will sink quickly. 
Osmotic Regulated Systems: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bio erodible capsule. In the stomach the capsule 
quickly disintegrates to release the intragastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic 
controlled drug delivery device consists of two components – drug reservoir 
compartment and osmotically active compartment. 
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1.4.FLOATING   DRUG   DELIVERY   SYSTEMS (FDDS) 
1.4.1. Advantages of FDDS25, 26: 
Floating dosage systems form important technological drug delivery systems with 
gastric retentive behavior and offer several advantages in drug delivery. These 
advantages include:  
1. Improved drug absorption, because of increased GRT and more time spent by 
the dosage form at its absorption site.  
2. Controlled delivery of drugs. 
3. Delivery of drugs for local action in the stomach.  
4. Minimizing the mucosal irritation due to drugs, by drug releasing slowly at   
controlled rate.  
5. Treatment of gastrointestinal disorders such as gastro-esophageal reflux.  
6. Simple and conventional equipment for manufacture.  
7. Ease of administration and better patient compliance.  
8. Site-specific drug delivery. 
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1.4.2. Disadvantages of FDDS:  
1. Gastric retention is influenced by many factors such as gastric motility, pH 
and presence of food. These factors are never constant and hence the 
buoyancy cannot be predicted. 
2. Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems. 
3. High variability in gastric emptying time due to its all or non-emptying 
process. 
4. Gastric emptying of floating forms in supine subjects may occur at random 
and becomes highly dependent on the diametric size. Therefore patients 
should not be dosed with floating forms just before going to bed.  
Floatable Drug Delivery Systems 8:   
Table.No:1. Lists of Drugs 
S. No. DOSAGE FORM                              DRUGS 
1 Microspheres Aspirin, Griseofulvin, p-nitroanilline, Ibuprofen, 
Terfinadine, Tranilast. 
2 Granules Diclofenac sodium, Indomethacin, Predmisolone 
3 Films Cinnarizine 
4 Powders Several basic drugs 
5 Capsules Chlordiazepoxide HCl, Diazepam, Furosemide, L-
Dopa, Benserazide, Misoprostol, Propranolol HCl, 
Ursodeoxycholic acid. 
6 Tablets/pills Acetaminophen, Acetylsalicylic acid, Amoxicillin 
trihydrate, Ampicillin, Atenolol, Chlorpheniramine, 
Cinnazirine, Diltiazem, Fluorouracil,  
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Table.No:2.  Marketed Products of FDDS 
 
1.4.3.TYPES   OF   FLOATING   DRUG   DELIVERY   SYSTEMS (FDDS) 36 
 Based on the mechanism of buoyancy, two distinctly different technologies 
have been utilized in development of FDDS which are: 
A. Effervescent System, and 
B. Non- Effervescent System. 
S. 
NO. 
Brand 
Name 
Drug (Dose) Company, 
Country 
Remarks 
1. Modapar Levodopa(100mg), 
Benserazide(25 mg) 
HRoche Products, 
USA 
Floating CR capsule 
2. Valrelease Diazepam (15 mg) Hoffmann-
LaRocheUSA 
Floating capsule 
3. Liquid 
Gavison 
Al hydroxide (95 mg),  
Mg carbonate (358 mg) 
GlaxoSmith Kline, 
India 
Effervescent floating 
liquid alginate 
preparation 4. Topalkan Al-Mg antacid Pierre Fabre Drug, 
France 
Floating liquid alginate 
preparation 
5. Conviron Ferrous sulphate Ranbaxy, India Colloidal gel forming 
FDDS 
6. Cifran OD Ciprofloxacin(1gm) Ranbaxy, India Gas-generating floating 
tablet 
7. Cytotec Misoprostal(10mcg/200
mcg) 
Pharmacia, USA Bilayer floating capsule 
8. Oflin OD Ofloxacin (400mg) Ranbaxy, India Gas generating floating 
tablet 
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EFFERVESCENT SYSTEM:- 
Effervescent systems include use of gas generating agents, carbonates (ex. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present 
in the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of 
the system and making it float on the gastric fluid. An alternative is the incorporation 
of matrix containing portion of liquid, which produce gas that evaporates at body 
temperature. 
These effervescent systems further classified into two types. 
I. Gas Generating systems  
II. Volatile Liquid/Vacuum Containing Systems. 
Gas – Generating Systems: 
Intra Gastric Single Layer Floating Tablets or Hydro dynamically Balanced 
System (HBS): 
 These are as shown in Fig.5 and formulated by intimately mixing the CO2 
generating agents and the drug within the matrix tablet.   These have a bulk density 
lower than gastric fluids and therefore remain floating in the stomach unflattering the 
gastric emptying rate for a prolonged period. The drug is slowly released at a desired 
rate from the floating system and after the complete release the residual system is 
expelled from the stomach. This leads to an increase in the GRT and a better control 
over fluctuations in plasma drug concentration.  
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Fig.No: 5. Intra Gastric Single Layer Buoyant Tablet. 
Intra Gastric Bilayer Floating Tablets: 
   These are also compressed tablet as shown in Fig 6 and containing two layers i.e,  
i. Immediate release layer and  
ii. Sustained release layer.   
 
Fig.No:6. Intra Gastric Bilayer Buoyant Tablet. 
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Multiple Unit type floating pills: 
 These systems consist of sustained release pills as ‘seeds’ surrounded by 
double layers. The inner layers consist of effervescent agents while the outer layer is 
of swellable membrane layer. When the system is immersed in dissolution medium at 
body temperature, it sinks at once and then forms swollen pills like balloons, which 
float as they have lower density. This lower density is due to generation and 
entrapment of CO2 within the system.  
 
Fig.No:7. A multi-unit oral buoyant dosage system. Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and floating;                
(C) dissolution of drug.  
Key: (a) conventional SR pills; (b) effervescent layer; (c) swellable layer; (d) 
expanded swellable membrane layer; (e) surface of water in the beaker (370C) 
  
INTRODUCTION 
 
Dept. of Pharmaceutics        20  JKKMMRF College of Pharmacy 
 
Volatile Liquid / Vacuum Containing Systems:23 
Intragastric Floating Gastrointestinal Drug Delivery System: 
 These systems can be made to float in the stomach because of floatation 
chamber, which may be a vacuum or filled with air or a harmless gas, while drug 
reservoir is encapsulated inside a micro porous compartment, as shown in Fig 8. 
  
Fig.No:8. Intra Gastric Floating Gastrointestinal Drug Delivery Device 
Inflatable Gastrointestinal Delivery Systems: 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause the chamber to inflate in the stomach. 
These systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug, impregnated polymeric matrix, then encapsulated in a gelatin 
capsule.  
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Fig.No:9. Inflatable Gastrointestinal Delivery System 
After oral administration, the capsule dissolves to release the drug reservoir 
together with the inflatable chamber. The inflatable chamber automatically inflates 
and retains the drug reservoir compartment in the stomach. The drug continuously 
released from the reservoir into the gastric fluid. This system is shown in Fig 9. 
Intragastric Osmotically Controlled Drug Delivery System:   
 It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule 
quickly disintegrates to release the intragastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic 
pressure controlled drug delivery device consists of two components; drug reservoir 
compartment and an osmotically active compartment.  
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 The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery 
orifice. The osmotically active compartment contains an osmotically active salt and is 
enclosed within a semi permeable housing. An osmotic pressure is thus created which 
acts on the collapsible bag and in turn forces the drug reservoir compartment to 
reduce its volume and activate the drug reservoir compartment to reduce its volume 
and activate the drug release of a drug solution formulation through the delivery 
orifice.  
 The floating support is also made to contain a bioerodible plug that erodes 
after a predetermined time to deflate the support. The deflated drug delivery system is 
then emptied from the stomach. This system is shown in Fig10. 
 
Fig.No:10.  Intragastric Osmotically Controlled Drug Delivery System 
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NON-EFFERVESCENT SYSTEMS: 23 
 The Non-effervescent FDDS based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming material such as Polycarbonate, Polyacrylate, 
Polymethacrylate, polystyrene as well as bioadhesive polymer such as Chitosan and 
Carbopol. The various types of this system are as: 
Single Layer Floating Tablets: 
 They are formulated by intimate mixing of drug with a gel-forming 
hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of 
less than unity. The air trapped by the swollen polymer confers buoyancy to these 
dosage forms.  
Bilayer Floating Tablets:  
A bilayer tablet contain two layer one immediate release layer which release 
initial dose from system while the another sustained release layer absorbs gastric 
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a bulk 
density of less than unity and thereby it remains buoyant in the stomach.    
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Alginate Beads: 
Multi unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of calcium chloride, 
causing precipitation of calcium alginate leading to formation of porous system, 
which can maintain a floating force for over 12 hours.  
Hollow Microspheres: 
Hollow microspheres (micro balloons), loaded with drug in their outer 
polymer shells were prepared by a novel emulsion-solvent diffusion method. The 
ethanol: dichloromethane solution of the drug and an enteric acrylic polymer was 
poured into an agitated aqueous solution of PVA that was thermally controlled at 
400C. The gas phase generated in dispersed polymer droplet by evaporation of 
dichloromethane formed an internal cavity in microsphere of polymer with drug. The 
micro balloons floated continuously over the surface of acidic dissolution media 
containing surfactant for more than 12 hours in-vitro. 
 
Fig.No:11. Hallow microspheres 
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2. LITERATURE REVIEW 
Narendra, et.al., 9 reported optimization of bilayer floating tablet containing 
Nevirapine as a model drug for gastric retention. They employed a 23 factorial design 
in formulating the GFDDS with total polymer content-to-drug ratio (X1), polymer-to-
polymer ratio (X2), and different viscosity grades of HPMC (X3) as independent 
variables. The results indicate that X1 andX2 -significantly affected the floating time 
and release properties but the effect of different viscosity grades of HPMC (K4M and 
K10M) was non-significant. 
Srivastava, et.al.,10 prepared floating matrix tablets of atenolol to prolong 
gastric residence time and increase drug bioavailability. The tablets were prepared by 
direct compression technique, using polymers such as HPMC K15M, K4M, Guar gum 
(GG), and sodium carboxy methylcellulose (SCMC), alone or in combination and 
other standard excipients. The effect of effervescent on buoyancy and drug release 
pattern was also studied. In-vitro release mechanism was evaluated by linear 
regression analysis. GG- and SCMC-based matrix tablets showed significantly greater 
swelling indices compared with other batches. The tablets exhibited controlled and 
prolonged drug release profiles. 
Dave, et.al.,11 reported a gastro retentive drug delivery system of ranitidine 
hydrochloride. Guar gum, Xanthan gum, and hydroxyl propyl methylcellulose were 
evaluated for gel forming properties. Sodium bicarbonate was incorporated as a gas-
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generating agent. They investigated the effect of citric acid and stearic acid on drug 
release profile and floating properties. They concluded that the proper balance 
between a release rate retardant and a release rate enhancer could produce a drug 
dissolution profile similar to a theoretical dissolution profile. 
Dalavi.V.V., et.al.,12 developed a Gastro retentive tablet of Zidovudine to 
enhance its bioavailability and sustained action. Zidovudine is a novel compound used 
in the treatment of HIV. In 32 factorial designs, amount of HPMC K4M (X1) and gas 
generating agents (X2) were selected as independent variable. The time required for 
50% drug release t50% (Y1) was selected as dependent variable. The results of 
factorial design showed that factor X1 and X2 significantly affect the studied 
dependent variables. The formulation with good floating time (24hrs) and the percent 
drug release (98.05) emerged as optimal. 
Sivabalan.M., et.al.,13  Formulated and evaluated hydro dynamically balanced 
controlled drug delivery system of Glipizide. The formula selected for design had a 
combination of Glipizide, HPMC, EC and MC. The tablets were prepared by direct 
compression method and evaluated for Glipizide content, in-vitro release profile and 
buoyancy. The buoyancy of the tablets was ranged between 10.917±0.4403hrs and 
16.237±0.1217 hrs, the maximum buoyancy was seen in G8, which has a high level of 
drug to polymer ratio. The in-vitro release was found to be in the range of 59.25% to 
79.50%. The Glipizide content in the formulation varied between 91–100%. The 
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formulation G8 has an in-vitro release of 59.25, showed the release of the drug in the 
controlled manner.  
Sunil K. Jain, et.al.,14  Prepared floating microspheres consisting of (1) 
calcium silicate as porous carrier; (2) orlistat, an oral anti-obesity agent; and (3) 
Eudragit S as polymer, by solvent evaporation method and to evaluate their gastro-
retentive and controlled-release properties. The effect of various formulation and 
process variables on the particle morphology, micromeritic properties, in-vitro 
floating behavior, percentage drug entrapment, and in-vitro drug release was studied. 
The microspheres were found to be regular in shape and highly porous. Microsphere 
formulation CS4, containing 200 mg calcium silicate, showed the best floating ability 
(88% ± 4% buoyancy) in simulated gastric fluid as compared with other formulations. 
Release pattern of orlistat in simulated gastric fluid from all floating microspheres 
followed Higuchi matrix model and Korsmeyer-Peppas model. The enhanced 
elimination half-life observed after pharmacokinetic investigations in the present 
study is due to the floating nature of the designed formulations. 
S. B. Bhise, et.al.,15 studied sustained release floating capsules for 
theophylline was fabricated using drug: polymer ratio of 30:70. The hydrocolloids 
were used in different proportions and four formulations were prepared. These 
formulations were optimized on the basis of buoyancy, matrix integrity, duration of 
floating and in-vitro drug release. All the four formulations showed good buoyancy 
and matrix integrity. The duration of floating was more than 12 h for all formulations. 
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In-vitro drug release study of these formulations indicated controlled release of 
theophylline and about 76 percent drug was released at the end of 12 h. 
Vishal G. Karkhile, et.al.,16 Floating tablet of Furosemide (FUR) was 
prepared by direct compression technique. Furosemide was chosen as model drug 
because it is slightly soluble in water and poorly absorb from lower intestine. PEG-
6000 is used as carrier agent for increasing solubility of Furosemide in water. 
Hydroxypropylmethylcellulose, sodium bicarbonate and carbopol were used as 
matrixing agent, gas generating agent and floating agent respectively. The tablets 
were evaluated for in-vitro buoyancy and dissolution studies. Tablets were evaluated 
for physical characteristics. The data of in-vitro dissolution study of prepared floating 
tablet formulation showed zero order plots which was found to be fairly linear as 
indicated by its high regression value (R2=0.9772 to 0.9911). The optimized floating 
tablet batch (F3) shows drug release in a controlled manner with higher dissolution 
for 12 hr. 
Patel, et.al.,17 prepared a floating drug delivery system of famotidine. 
Famotidine having poor absorption in acidic environment (upper GIT). When given 
orally, it shows the bioavailability near to 50%. To overcome these drawbacks, the 
present study was undertaken to investigate the floating dosage form of famotidine. 
Floating tablets were prepared using Direct Compression. Six formulations were 
prepared containing gel-forming agent (HPMC K4M) and retardant (Na-CMC) in 
different ratio and it was found that gas generating agent (NaHCO3) reacts with HCl 
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and liberates CO2 which creates pores in tablet and elevates swelling and maintains 
buoyancy. The prepared tablets were evaluated for content uniformity, hardness, 
friability, buoyancy, swelling index and in-vitro dissolution studies. Further selected 
formulation was subjected for short term stability studies for one and two month at 
temperature of 25°c and 40°c respectively. 
Chander Shekar, et.al.,18 Prepared a gastro retentive drug delivery system of 
Ketoconazole by direct compression technology. HPMC K100LV, HPMC K15M, 
Ethyl Cellulose and effervescent sodium bicarbonate formed the floating tablet. The 
prepared tablets exhibited satisfactory physico-chemical characteristics. Final 
formulation released approximately 89.21% drug in 24 h in-vitro, while the floating 
lag time was not more than 35 Sec and the tablet remained floatable throughout all 
studies. The tablets with HPMCK15M were found to float for longer duration as 
compared with formulations containing HPMCK 4 M. The release of Ketoconazole 
was found to follow a mixed pattern of Korsmeyer-Peppas, Hixson-Crowell and zero 
order release models. The optimized formulation was found to be buoyant for 24 hr in 
stomach. The drug release from the tablets was sufficiently sustained and non-Fickian 
transport of the drug from tablets was confirmed.  
Pramod Patil, et.al.,19 developed floating tablets of ofloxacin which were 
designed to prolong the gastric residence time after oral administration. Ofloxacin 
floating tablets were prepared by wet granulation method incorporating natural 
polymer like guar gum, locust bean gum, either alone or in combination with HPMC 
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K100M as swelling polymers, with sodium bicarbonate as gas generating agent and 
were evaluated for physico-chemical parameters. All the formulation showed 
compliance with pharmacopeia standards. Based on the evaluation results, F3 and F6 
formulations were selected as the best formulations and were checked for stability as 
per ICH guidelines. These results indicated that the selected formulations were stable. 
The drug release of optimized formulation follows theHiguchi kinetic model, and the 
mechanism is found to be non-Fickian/anomalous according to Korsmeyer–
Peppasequation. 
Tarique khan, et.al.,20 studied development and in-vitro evaluation of the 
floating matrix tablets, which after oral administration can prolong the gastric 
residence time, increase the drug bioavailability. A polymer (sodium carboxy methyl 
cellulose or hydroxyl propyl methylcellulose K4M, K15M) was added to control the 
drug release. The time to flotation could be controlled by the composition (type of 
filler, concentration of effervescent agents) and hardness of the tablet. Six different 
formulations were prepared i.e. D1, D2, D3, D4, D5, and D6 by varying the polymers 
ratio. All the formulations were evaluated for physico-chemical parameters. The 
formulation D4 shows 99% drug release at the end of 12 h in-vitro and floating lag 
time was 30 sec and tablet remained buoyant throughout studies. 
Thakkar, et.al.,21 Formulated and evaluated the levofloxacin hemihydrates 
floating tablets that were prepared by direct compression method using gelucire 43/01 
and HPMC polymers in different ratio. The in-vitro release study revealed the fact 
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that the release rate of drug was decreased by increasing the proportions of gelucire 
43/01 by 5 to 40% matrix tablets containing 25% HPMCK4M and 15% gelucire 
43/01.  
Bomma, et.al.,22 Prepared floating matrix tablets of norfloxacin which were 
developed to prolong gastric residence time leading to an increase in drug 
bioavailability by using wet granulation technique using polymers such as 
HPMCK4M, HPMCK100M and Xanthan gum. The tablets exhibited controlled and 
prolonged drug release profile while floating over dissolution medium was confirmed 
as drug release mechanism from these tablets.  
Rahman, et.al.,23 Developed a bilayer-floating tablet (BFT) for captopril 
using direct compression technology. HPMC-K15Mgrade and effervescent mixture of 
citric acid and sodium bicarbonate formed the floating layer. The release layer 
contained captopril and various polymers such as HPMC-K15M, PVP-K30 and 
Carbopol 934P, alone or in combination with the drug. Final formulation released 
approximately 95% drug in 24 h in-vitro, while the floating lag time was 10 min and 
the tablet remained floatable throughout all studies. Final formulation followed the 
higuchi release model and showed no significant change in physical appearance, drug 
content, floatability or in-vitro dissolution pattern after storage at 45 °C/75% RH for 
three months.  
Amin, et.al.,24 developed a gastro retentive drug delivery system of ranitidine 
hydrochloride which was designed using guar gum, xanthan gum and HPMC. Sodium 
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bicarbonate was incorporated as a gas-generating agent. The effect of citric acid and 
stearic acid on drug release profile and floating properties was investigated. The 
addition of stearic acid reduces the drug dissolution due to its hydrophobic nature. A 
3
2
full factorial design was applied to systemically optimize the drug release profile 
and the results showed that a low amount of citric acid and a high amount of stearic 
acid favor sustained release of ranitidine HCl from a gastro retentive formulation.  
Li, et.al.,25 Formulated using 2x3 full factorial designs for calcium delivery. 
HPMC was used as a low-density polymer and citric acid was incorporated for gas 
generation. Analysis of variance (ANOVA) test on the results from these 
experimental designs demonstrated that the hydrophobic agent magnesium stearate 
could significantly improve the floating capacity of the delivery system. High-
viscosity polymers had good effect on floating properties. The residual floating force 
values of the different grades of HPMC were in the order K4 M~ E4 M~K100 LV> 
E5 LV but different polymers with same viscosity, i.e., HPMC K4M, HPMC E4M did 
not show any significant effect on floating property. Better floating was achieved at a 
higher HPMC/Carbopol ratio and this result demonstrated that Carbopol has a 
negative effect on the floating behavior.  
J.Sahoo, et.al.,26 Studied the release of Propranolol hydrochloride from matrix 
tablets with hydroxy propyl methyl cellulose (HPMC K15M) or Kollidon®SR at 
different concentrations was investigated with a view to developing twice daily 
sustained release dosage form using direct compression technique. The resulting 
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matrix tablets prepared with HPMC K15M or Kollidon®SR fulfilled all the official 
requirements of tablet dosage forms. Formulations were evaluated for the release of 
Propranolol hydrochloride over a period of 12 h in pH 6.8 phosphate buffer using 
USP type II dissolution apparatus. Propranolol hydrochloride and pure Kollidon®SR 
or HPMC K15M compatibility interactions was investigated by using FTIR 
spectroscopy and DSC and, these  studies revealed that there was no well defined 
chemical interaction between Propranolol hydrochloride with Kollidon®SR or HPMC 
K15M. Tablets were exposed to 40 °C/75% of RH in open disc for stability. The in-
vitro drug release study revealed that HPMC K15 at a concentration of 40% of the 
dosage form weight was able to control the release of Propranolol hydrochloride for 
12 h, exhibit non-Fickian diffusion with first-order release kinetics where as at 40% 
Kollidon®SR same dosage forms show zero-order release kinetics.  
Narasaiah, et.al.,27 prepared a gastro-retentive drug delivery system of 
Sumatriptan Succinate as a model drug. The floating tablets were prepared by wet 
granulation method using hydroxy propyl methylcellulose (HPMC) as gel-forming 
agent. Sodium bicarbonate and citric acid were incorporated as gas-generating agents. 
The tablets were physically characterized and evaluated for in-vitro release 
characteristics for 8 hrs in 0.1N HCl at 37°C. The physical characterization of the 
tablets was found within the limits. By comparing dissolution profiles, the 
formulation F5 was considered as a better formulation. The drug release for all the 
formulations were followed by zero order kinetics and Peppas modeling. The 
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diffusion exponent of formulations was found (n<0.89) to be non-fickian 
(Anomalous) diffusion mechanism.  
AJ.Shinde, et.al.,28 prepared a gastro retentive floating drug delivery system 
(GFDDS) of cephalexin (CFL) employing the hydrophilic polymer hydroxy propyl 
methylcellulose (HPMC), gas generating agent sodium bicarbonate and citric acid. A 
32 factorial design was applied systematically; the amount of citric acid (X1) and 
amount of HPMC K100M (X2) were selected as independent variables. The time 
required for 50% drug release (t50%), percentage drug release at 12 hours (Q12) and 
percentage drug release at 6 hours (Q6) were selected as dependent variables. The 
results of factorial design indicated that high level of HPMC K100M and citric acid 
favors preparation of floating sustained release tablet of cephalexin. The granules 
were prepared by wet granulation method and evaluated for their granules properties. 
Tablets were compressed by Mini press rotary tablet machine and evaluated with 
different parameters like diameter, thickness, average weight, hardness, friability, 
drug content, in-vitro buoyancy study, swelling characteristics, scanning electron 
microscopy, and kinetic release data. The tablets containing CFL released 72.28 to 
99.461 % of drug at the end of 12 hrs by in-vitro release study. The drug release from 
the tablets was sufficiently sustained followed the Korsmeyer-Peppas model 
controlled mechanism of cephalexin tablet. 
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3. AIM AND OBJECTIVE 
The present work is aimed to formulate Zanamivir floating tablets using 
different hydrophilic and hydrophobic polymers like HPMC, Ethyl cellulose, 
Xanthum gum, guar gum and gas generating agent Sodium bicarbonate. 
 The objective of the present work is to develop Gastro retensive dosage form 
that could retain the anti- viral agent namely Zanamivir in the stomach for longer 
periods of time delivering the drug to the site of action, i.e., stomach. 
            Zanamivir is an anti-viral agent. It is soluble in water with 75% 
bioavailability. HPMC is used as a swelling agent, Guar gum and Xanthum gum is 
used as binding agent. Ethyl cellulose is used as matrix form agent.  PVP is used as a 
suspending agent. sodium bicarbonate is used as a gas forming agent. MCC is used as 
a disinter grant and diluent. Magnesium stearate is used as a lubricant. 
         The prepared Zanamivir tablets will be evaluated for drug content, entrapment 
efficiency, particle size analysis, post compression studies, In-vitro buoyancy studies, 
swelling index studies, in-vitro dissolution studies, release kinetics, stability studies. 
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4. PLAN OF THE WORK 
The plan of work was given below 
 Preformulation studies. 
1. Identification of drug 
2. Drug – Excipients compatibility studies by FTIR 
spectrophotometry 
3. Pre compression studies 
 Formulation of floating tablets of  Zanamivir. 
 Evaluation studies 
 Post compression studies 
 Drug content 
 In-vitro buoyancy studies 
 Swelling index studies 
 In-vitro dissolution studies 
 Release kinetics 
 Stability studies 
DRUG AND POLYMER PROFILES 
 
Dept. of Pharmaceutics        37  JKKMMRF College of Pharmacy 
 
5. DRUG AND POLYMER PROFILES 
5.1. DRUG PROFILE 
ZANAMIVIR 
Description  : An acetamido cyclohexene that is a structural homolog of sialic acid 
and inhibits neuraminidase. 
 
 
 
 
Structure   Formula  :                                     
Synonyms : Zanamivir phosphate 
Categories :   Antiviral Agents 
 Enzyme Inhibitors 
 Weight:Average:332.31 
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Chemical Formula  : C12H20N4O7 
IUPAC Name : (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-
trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid 
TAXONOMY 
Kingdom : Organic 
Classes          : Carboxylic Acids and Derivatives 
Cyclohexenes and Derivatives 
Carboxylic Acids and Derivatives 
Alkanes and Alkenes 
             Acetates 
Substructure : Amino Ketones 
                          Aliphatic and Aryl Amines 
                          Ethers 
 Carboxamides and Derivatives 
Cyclohexenes and Derivatives 
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PHARMACOLOGY 
Indication : Zanamivir (Relenza) is for the treatment of uncomplicated acute illness 
due to influenza infection in patients 1 year and older who have been symptomatic for 
no more than 2 days. It is also used for the prophylaxis of influenza in adult patients 
and adolescents 13 years and older 
Pharmacodynamics : Zanamivir is an antiviral drug, a neuraminidase inhibitor used 
in the treatment and prophylaxis of both influenza A and influenza B. Zanamivir is a 
prodrug (usually administered as phosphate), it is hydrolysed hepatically to the active 
metabolite, the free carboxylate of zanamivir (GS4071). Like zanamivir, zanamivir 
acts as a transition-state analogue inhibitor of influenza neuraminidase. 
Mechanism of action  : Zanamivir is an ethyl ester prodrug requiring ester hydrolysis 
for conversion to the active form, zanamivir carboxylate. The proposed mechanism of 
action of zanamivir is inhibition of influenza virus neuraminidase with the possibility 
of alteration of virus particle aggregation and release. 
  Absorption : Readily absorbed from the gastrointestinal tract after oral 
administration with a bioavailability of 75%. 
Volume of distribution  : 23 to 26 L 
Protein binding : Zanamivir carboxylate: low (3%), Zanamivir free base: 42%. 
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Metabolism : Extensively converted to zanamivir carboxylate by esterases located 
predominantly in the liver. Neither zanamivir nor zanamivir carboxylate is a substrate 
for, or inhibitor of, cytochrome P450 isoforms. At least 75% of an oral dose reaches 
the systemic circulation as zanamivir carboxylate. 
Route of elimination : Absorbed zanamivir is primarily (>90%) eliminated by 
conversion to zanamivir carboxylate. Zanamivir carboxylate is not further 
metabolized and is eliminated in the urine. Zanamivir carboxylate is eliminated 
entirely (>99%) by renal excretion. 
Half life : 1 to 3 hours in most subjects after oral administration. 
Clearance : Not Available 
Toxicity : At present, there has been no experience with overdose. Single doses of up 
to 1000 mg of zanamivir have been associated with nausea and/or vomiting. Mean LD 
(intravenous, mouse) = 100 mg/kg. 
Affected organisms : Influenza Virus 
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5.2. POLYMER PROFILE 
5.2.1.HYDROXY PROPYL METHYL CELLULOSE 
Non-proprietary names:  Bp: Hypromellose 
USP: Hydroxy propyl methyl cellulose  
Synonyms: Methyl hydroxy propyl cellulose, propylene glycol either of 
methylcellulose, methylcellulose, methylcellulose propylene glycol ether.  
Chemical name:  
Cellulose, 2-hydroxypropyl-methyl ether  
Empirical formula:  
C8H15O6 – (C10H18O6) n – C8H15O5  
Description: It occurs as odorless and tasteless creamy white colored fibrous or 
glandular powder.  
FUNCTIONAL CATEGORY: Coating agent, film former, tablet binder, stabilizing 
agent, suspending agent, viscosity  increasing agent.  
Density:  0.25 – 0.70 g/cm3  
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Solubility: Soluble in cold water forming viscous colloidal solution, insoluble in 
chloroform, ethanol and ether, but soluble in mixtures of ethanol and methylene 
chloride.  
Viscosity:   HPMC K4M; HPMCK15M. HPMC K100M; 
Stability and storage: It is stable although it is slightly hygroscopic. The bulk 
material should be stored in airtight container in a cold and dry place. Increase in 
temperature reduces the viscosity of the solution.  
Safety: It is widely used in many oral and topical pharmaceutical formulations. It is 
generally regarded as a non-toxic and non-irritant material, although excessive 
consumption may have laxative effect. 
Pharmaceutical Applications:  
1. Film-former in tablet film coating: Lower viscosity grades are used in 
aqueous film coating and higher viscosity grades are used in solvent film 
coating. 
2. Binder in tablet granulations: 2.5% high-viscosity grades are used to retard 
the release of water-soluble drugs. 
3. As a Thickening agent: Thickening agent added to   vehicles for eye drops & 
artificial fear solutions at 0.45 - 1.0% concentrations. 
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4. As a protective colloid: Prevents droplets and particles from                                      
Coalescing or agglomerating, thus inhibiting the formation of sediments. It is 
used as emulsifier, suspending agent & stabilizer in gels & ointments. As an 
adhesive in plastic bandages. 
5.2.2. SODIUM BICARBONATE 
Non-proprietary names:    BP/EP: sodium bicarbonate  
Synonym:     Baking soda, e-500, and monosodium carbonate.  
Chemical name:    carbonic acid, monosodium salt, monosodium carbonate.  
Empirical formula:   NaHCO3  
Molecular weight:    84.01  
Category:     alkalizing agent, therapeutic agent.  
Description:    it is an odorless, white crystalline powder with slight alkaline taste.  
Acidity/ alkalinity:  pH 8.3 for freshly prepared 0.1m aqueous solution at 250c.  
Density:  2.159 g/cm3  
Solubility:   Soluble in water, practically insoluble in ethanol.  
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Stability and storage: Sodium bicarbonate is stable in dry air but slowly decomposes 
in moist air and should therefore be stored in well-closed container in a cool dry 
place.  
Safety: Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution 
of carbon dioxide and may cause stomach cramps and flatulence.  
Applications:   
1. Employed as a source of carbon dioxide in effervescent tablets and 
granules.
 
2. Also used to buffer the drug molecules that are weak acids.
 
3. Used in solutions as buffering agent.
 
4. Also used as freeze-drying stabilizer.
 
5. As a gas forming agent.
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5.2.3.MICROCRYSTALLINE CELLULOSE
 
Empirical formula:   (C 6H10 O5) 
Molecular weight:   n~220 
Category: Adsorbent; suspending agent, tablet and capsule diluents, tablet 
disintegrate. 
Description: Itoccurs as a white, odorless, tasteless, crystalline powder composed of 
porous particles.  
Density (true):  1.512-1.668 g/cm3 
Solubility:     Slightly soluble in 5% W/V sodium hydroxide solution 
Application in pharmaceutical Formulation Technology  
1. Microcrystalline cellulose is widely used in pharmaceuticals primarily as 
binder/diluents in oral tablet and capsule formulations. 
2. Microcrystalline cellulose also has some lubricant and disintegrates 
properties that make it useful in tabulating.  
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Table.No:3.Use of MCC 
 
Safety: Microcrystalline cellulose is not absorbed systemically following oral 
administration and thus has little toxic potential. Consumption of large quantities of 
cellulose may, however, have a laxative effect, although this is unlikely to be a 
problem when cellulose is used as an excipient in pharmaceutical formulation 
5.2.4.MAGNESIUM STEARATE 
Synonyms:      Stearic acid magnesium salt,  
                         Magnesium octa decanoate   
Chemical name: Octdecanoic acid magnesium salt 
Nonproprietary names: BP- Magnesium stearate  
Use Concentration (%) 
Adsorbent 20-90 
Anti-adherent 5-20 
Capsule binder/ diluent 20-90 
Tablet disintegrate 5-15 
Tablet binder/ diluent 20-90 
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PHEUR-Magnesia stearate  
 USP NF - magnesium stearate.  
Description:    Magnesium stearate is a fine, white, precipitated, milled, impalpable 
powder of   low bulk density, having a faint, characteristic odor and taste. The powder 
is greasy to touch and readily adheres to skin.  
Applications:  
1. Magnesium stearate is widely used in cosmetics, foods and pharmaceuticals.  
2. It is primarily used as lubricant in capsule and tablet manufacture at a 
concentration between 0.25-5.0 % concentrations. 
3. As an excipient, it is mainly used as directly compressible tablet diluents. 
4. Also used in micro sphere formulations. 
5. Used to absorb liquids, such as flavors in tabulating process. 
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5.2.5.ETHYL CELLULOSE 
Nonproprietary Names 
BP: Ethylcellulose 
PhEur: Ethylcellulose 
USP-NF: Ethylcellulose 
Synonyms 
Aquacoat ECD;Aqualon;Ashacel; E462;Ethocel; ethylcellulosum; Surelease. 
Chemical Name  
Cellulose ethyl ether  
Empirical Formula and Molecular Weight 
Ethylcellulose is partially ethoxylated. Ethylcellulose with complete ethoxyl 
substitution (DS = 3) is C12H23O6(C12H22O5)nC12H23O5 where can vary to provide a 
wide variety of molecular weights. Ethylcellulose, an ethyl ether of cellulose, is a 
long-chain polymer ofb-anhydroglucose units joined together by acetal linkages. 
  
DRUG AND POLYMER PROFILES 
 
Dept. of Pharmaceutics        49  JKKMMRF College of Pharmacy 
 
Structural Formula 
 
Functional Category 
Coating agent; flavoring agent; tablet binder; tablet filler; viscosityincreasing agent. 
Applications in Pharmaceutical Formulation or Technology 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations. 
The main use of ethylcellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. 
Ethylcellulose coatings are used to modify the release of a drug,to mask an 
unpleasant taste, or to improve the stability of a formulation; for example, where 
granules are coated with ethylcellulose to inhibit oxidation. Modified-release tablet 
formulations may also be produced using ethylcellulose as a matrix former. 
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Ethylcellulose, dissolved in an organic solvent or solvent mixture, can be used 
on its own to produce water-insoluble films. Higher-viscosity ethylcellulose grades 
tend to produce stronger and more durable films. Ethylcellulose films may be 
modified to alter their solubility,by the addition of hypromellose or a plasticizer;. An 
aqueous polymer dispersion (or latex) of ethylcellulose such as Aquacoat ECD (FMC 
Biopolymer) orSurelease(Colorcon) may also be used to produce ethylcellulose films 
without the need for organic solvents. Drug release through ethylcellulose-coated 
dosage forms can be controlled by diffusion through the film coating. This can be a 
slow process unless a large surface area (e.g. pellets or granules compared with 
tablets) is utilized. In those instances, aqueous ethylcellulose dispersions are generally 
used to coat granules or pellets. Ethylcellulose-coated beads and granules have also 
demonstrated the ability to absorb pressure and hence protect the coating from 
fracture during compression. 
High-viscosity grades of ethylcellulose are used in drug microencapsulation. 
Release of a drug from an ethylcellulose microcapsule is a function of the 
microcapsule wall thickness and surface area. In tablet formulations, ethylcellulose 
may additionally be employed as a binder, the ethylcellulose being blended dry or 
wetgranulated with a solvent such as ethanol (95%). Ethylcellulose produces hard 
tablets with low friability, although they may demonstrate poor dissolution. 
Ethylcellulose has also been used as an agent for delivering therapeutic agents from 
oral (e.g. dental) appliances.In topical formulations, ethylcellulose is used as a 
thickening agent in creams, lotions, or gels, provided an appropriate solvent is 
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used.Ethylcellulose has been studied as a stabilizer for emulsions.Ethylcellulose is 
additionally used in cosmetics and food products. 
Table.No:4.Uses of ethylcellulose. 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
 
Description 
Ethylcellulose is a tasteless, free-flowing, white to light tan-colored powder. 
Solubility 
Ethylcellulose is practically insoluble in glycerin, propylene glycol, and water. 
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform,methyl acetate, and tetrahydrofuran, and in mixtures of aromatic 
hydrocarbons with ethanol (95%). Ethylcellulose that contains not less than 46.5% of 
ethoxyl groups is freely soluble in chloroform, ethanol (95%), ethyl acetate, 
methanol,and toluene 
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5.2.6. POVIDONE 
NonproprietaryName: Povidone 
Synonyms: Kollidon; plasdone; polyvinylpyrrolidone 
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula: (C6H9NO) n 
Molecular Weight: 2500–3 000 000 
Functional Category: Disintegrant; dissolution enhancer; suspending agent; tablet 
binder. 
Description: Povidone occurs as a fine, white to creamy-white colored, odorless or 
almost odorless, hygroscopic powder. Povidone with K-values equal to or lower than 
30 are manufactured by spray-drying and occur as spheres. Povidone K90 and higher 
K value povidone are manufactured by drum drying and occur as plates. 
Solubility: Freely soluble in acids, chloroform, ethanol (95 %), ketones, methanol, 
and water; practically insoluble in ether, hydrocarbons, and mineral oil. 
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Stability and Storage Conditions: Povidone darkens to some extent on heating at 
150°C, with a reduction in aqueous solubility. It is stable to a short cycle of heat 
exposure around 110–130°C. 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. As the powder is hygroscopic, it should be stored in an 
airtight container in a cool, dry place. 
Incompatibilities: Povidone is compatible in solution with a wide range of inorganic 
salts, natural and synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, tannin, 
and other compounds. 
Applications: Although povidone is used in a variety of pharmaceutical formulations, 
it is primarily used in solid-dosage forms. It is used as a tablet binder, tablet diluent or 
coating agent in the concentration of 0.5-5 %. Povidone is used as a suspending and 
dispersing agent in the concentration of 5 %. 
Related Substances: Crospovidone. 
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5.2.7. GUAR GUM 
 
Nonproprietary Names: 
BP, PhEur                      :   Guar Galactomannan  
USP-NF                         :   Guar Gum 
Synonyms                      :   Galactosol, Guarflour, Jaguargum, Meyprofin. 
Chemical name             :  Galactomannan polysaccharide. 
Molecular Formula     :   (C6H12O6)n 
Molecular Weight         :   220 000 
Density                            :   1.492g/cm3 
Viscosity                         :    4.86 Pa s (4860 cP) for a 1% w/v dispersion. 
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Description                   :     Occurs as an odorless, white to yellowish color,                             
            bland taste. 
Solubility                   :  Practically insoluble in organic solvents. In cold or hot 
water, disperses and swells almost immediately to forma 
highly viscous, thixotropic solution. 
Functional category    :  Suspending agent, binder, disintegrator and viscosity 
agent. 
Safety                        :  Guar gum is widely used in foods, and oral and topical                                                   
pharmaceutical formulations. Excessive consumption may 
cause  gastrointestinal  disturbance such as  diarrhea 
ornausea[42]. It is  nontoxic and nonirritant material.                                                                                  
Stability and storage  : The aqueous guar gum dispersion has a buffering action 
and are stable at pH 4-10.5. The guar gum powder should 
be stored  in a well closed container in a cool dry place. 
Pharmaceutical Applications  
1. Guar gum is commonly used in cosmetics, food products and pharmaceutical         
formulations[43].  
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2. It has also been investigated in the preparation of sustained release matrix 
tablets[43]. 
3.  Guar gum is used in solid dosage forms as a binder and disintegrant.  
4.  It is used by suspending, thickening, and stabilizing agent. 
5.  Guar gum also used by controlled released carrier. 
6.  It has also been examined for use in colonic drug 
5.2.8.XANTHAN GUM 
 
Nonproprietary Names:  
BP, USP-NF :  Xanthan Gum 
Synonyms    : Corn sugar gum, Xanthani gummi. 
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Chemical Name              : Xanthum Gum 
Molecular Formula        : (C35H49O29)n 
Molecular Weight           : 1×106 
Viscosity                          :   1200–1600 mPa s (1200–1600 cP) for a 1% w/v                                    
aqueous solution at 25°C.  
Description                     :    Xanthan gum occurs as a cream- or white-colored, 
  odorless, free flowing, fine powder. 
Solubility                          :    Practically insoluble in ethanol and ether; soluble in 
cold or warm water. 
Functional Category     :   Gelling agent; stabilizing agent; suspending agent;  
sustained- release agent; viscosity-increasing agent. 
Safety                    :  Xanthan gum is widely used in oral and topical 
pharmaceutical formulations, cosmetics, and food 
products, generally regarded as nontoxic and nonirritant 
material.     
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Stabilty & Storage           : Xanthan gum is a stable material. Aqueous solutions are 
stable overa wide pHrange(pH 3–12), maximumstability 
at pH 4–10 and temperatures of 10–60°Calthough they 
demonstrate. The bulk material should be stored in a 
well-closed container in a cool, dry place. 
Pharmaceutical Applications   
1. It is also used as a thickening and emulsifying agent.  
2. Xanthan gum has been used as a binderand in combination with Konjac 
glucomannanis used as an excipient for controlled colonic drug delivery. 
3. Xanthan gum has also been used with guar gum for the development of a 
floating drug delivery system 
4. Xanthan gum can be used to increase the bioadhesive strength in vaginal 
formulations. 
5. Xanthan gum can also be used as an excipient for spray-drying and freeze-
drying processes for better results. 
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6. METHODOLOGY 
6.1.MATERIALS USED 
           A.List of Materials used in the formulation 
Table.No:5.List of Materials used in the formulation 
1 ZANAMIVIR Chandra labs, Hyderabad 
2 HPMC  Sisco research laboratories 
Pvt.Ltd Mumbai 
3 XANTHUM GUM  MYL CHEM Mumbai 
4 GUAR GUM MYL CHEM Mumbai 
5 PVP Sisco research laboratories 
Pvt.Ltd Mumbai 
6 ETHYL CELLULOSE MYL CHEM Mumbai 
7 SODIUM BICARBONATE SD Fine Chemicals Ltd., 
Mumbai 
8 MICRO CRYSTALLINE 
CELLULOSE 
SD Fine Chemicals Ltd., 
Mumbai 
9 MAGNESIUM STEARATE SD Fine Chemicals Ltd., 
Mumbai 
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B.EQUIPMENTS USED 
                   Table.No:6.List of Equipment used for the formulation 
S. No Name of the Equipment Manufactured by 
1 Dissolution apparatus Electro Lab 
2 Tablet punching machine Cad mach 
3 U.V. Spectrophotometer Analytical 
4 Analytical Balance 
Adair Dutt Instruments Pvt. Ltd., 
AD50B 
5 Friability Apparatus Electro Lab 
6 Hardness tester Ketan 
7 FT-IR Spectrometer Bruker 
 
6.2. PREFORMULATION STUDIES 
Pre-formulation testing is an investigation of physical and chemical properties 
of a drug substance alone and when combined with excipients. 
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Pre-formulation studies yield necessary knowledge to develop suitable 
formulation for toxicological use. It gives information needed to define the nature of 
the drug substance and provide a dosage form. Hence, the following pre-formulation 
studies were performed for the obtained sample of drug. 
Description and Solubility 
Zanamivir  is a white crystalline powder. It was found to be Highly soluble in 
water. 
6.3.STANDARD GRAPH OF ZANAMIVIR 
A.Standard Stock solution: 100 mg of zanamivir was dissolved in 100 ml of 0.1N 
HCL (1000 μg/ml) 
Calibration curve of Zanamivir  in 0.1N HCL 
 From the above stock solution, 1 ml was transferred into a 10 ml volumetric 
flask and volume was adjusted to 10 ml that corresponded to 100 µg/ml zanamivir in 
solution. From that solution different aliquots of 1.6, 1.8, 2, 2.2 and 2.4 ml were 
transferred to 10ml volumetric flask, volume was adjusted with 0.1N HCL, which 
gave a concentration of 16,18,20,22 and 24 µg/ml of final standard. Standard curve 
was plotted by taking absorbance of secondary stock solutions in UV double beam 
spectrophotometer at 216 nm. 
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B.Drug-Excipients Compatiblity study: 
Zanamivir was mixed with all excipients, used in the formulation in different 
ratios and subjected to Physical observation/FTIR. 
Drug-Excipient Compatiblity study (FTIR):  
 The IR absorption spectra of the pure drug and with different excipients were 
taken in the range of 4000-400 cm-1 using KBr disc method, 1-2 mg of the substance 
to be examined was triturated with 300-400 mg, specified quantity, of finely powered 
and dried potassium bromide .These quantities are usually sufficient to give a disc of 
10-15mm diameter and pellet of suitable intensity by a hydraulic press.  
6.4. EXPERMENTAL METHODS 
FORMULATION AND PREPARATION OF ZANAMIVIR FLOATING 
TABLETS: All the formulations were prepared by direct compression method using 
different Polymers. 
PROCEDURE:  
1. Zanamivir and all other ingredients were individually passed through      
sieve  60. 
2. All the ingredients were mixed thoroughly by triturating up to 15 min. 
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3. The powder mixture was lubricated with Magnesium stearate The tablets were 
prepared by using direct compression method according to the formulation 
table. 
Table.No:7.Composition of different formulations 
Ingredients 
(mg) 
F1 F2 F3 F4 F5 F6 
Zanamivir 75 75 75 75 75 75 
HPMC 105 122.5 140 -- -- -- 
Xanthum gum -- --  105 -- -- 
Guar gum -- --  -- 105 -- 
Ethyl cellulose -- --  -- -- 105 
PVP 17.5 17.5 17.5 17.5 17.5 17.5 
Sodium 
bicarbonate 
52.5 52.5 52.5 52.5 52.5 52.5 
MCC 96.5 79 61.5 96.5 96.5 96.5 
Magnesium 
stearate 
3.5 3.5 3.5 3.5 3.5 3.5 
Total weight 350mg 350mg 350mg 350mg 350mg 350mg 
 
PVP – Poly vinyl pyrrolidine , HPMC- Hydroxy Propyl methyl cellulose,  
MCC- Micro crystalline cellulose 
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6.5. EVALUATION OF PRE COMPRESSION PARAMETERS 
A. Bulk density 
Bulk density of a compound varies substantially with the method of 
crystallization, milling or formulation. Bulk density is determined by pouring pre 
sieved granules into a graduated cylinder via a large funnel and measure the volume 
and weight. 
Bulk density =                   Weight of granules 
                                                 Bulk volume of granules 
Bulk density was expressed in g/cc. 
B. Tapped density: 
              Tapped density is determined by placing a graduated cylinder containing a 
known mass of granules and mechanical tapper apparatus, which is operated for a 
fixed number of taps until the powder bed volume has reached a minimum volume. 
using the weight of the drug in the cylinder and this minimum volume, the taped 
density may be computed. 
Tapped density   =                     Weight of granules 
                                                     Tapped volume of granules 
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C. Carr’s Index (CI):  
 Carr’s index is measured using the values of bulk density and tapped density. 
The following equation is used to find the Carr’s index. 
CI =                     (TD-BD) x100 
                            TD 
 Where TD = Tapped density 
 BD = Bulk density 
Table.No:8.Flow properties and corresponding Carr’s Index values 
Excellent <10 
Good 11 – 15 
Fair 16 – 20 
Possible 21 – 25 
Poor 26 – 31 
Very poor 32 – 37 
Very very poor >38 
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D.Hausner’s Ratio: 
It indicates the flow properties of the powder and ratio of Tapped density to 
the Bulk density of the powder or granules.  
Hausner’s Ratio = Tapped density / Bulk density 
Table.No:9.Flow Properties and Corresponding Hausner’s ratio 
Excellent 1.00 – 1.11 
Good 1.1 – 1.18 
Fair 1.19 – 1.25 
Possible 1.26 -1.34 
Very poor 1.35 -1.45 
Very very poor >1.60 
 
E.Angle of repose: 
The manner in which stresses are transmitted through a bead and the beads 
response to applied stress are reflected in the various angles of friction and response. 
The method used to find the angle of repose is to pour the powder ion a conical heat 
on a level, flat surface and measure the included angle with the horizontal. 
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Tanθ = h/r 
Where,     h= height of the heap 
                    r= Radius of the heap 
 
Table.No:10. Flow Properties and Corresponding Angle of Repose 
ANGLE OF REPOSE POWDER FLOW 
< 25 Excellent 
25 – 30 Good 
30 – 40 Passable 
> 40 Very poor 
 
6.6.EVALUATION OF TABLETS38:  
The formulated tablets were evaluated for the following physicochemical 
characteristics:  
A.General appearance:   
The formulated tablets were assessed for its general appearance and 
observations were made for shape, color, texture and odor.   
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B.Hardness:   
Hardness of the tablet was determined by using the Monsanto hardness tester. 
The lower plunger was placed in contact with the tablet and a zero reading was taken. 
The plunger was then forced against a spring by turning a threaded bolt until the tablet 
fractured. As the spring was compressed a pointer rides along a gauge in the barrel to 
indicate the force.  
C.Weight Variation:  
 
Fig.No:12.Weight Variation Apparatus 
20 tablets were selected and weighed collectively and individually. From the 
collective weight, average weight was calculated. Each tablet weight was then 
compared with average weight to ascertain whether it was within the permissible 
METHODOLOGY 
 
Dept. of Pharmaceutics        69  JKKMMRF College of Pharmacy 
 
limits or not. Not more than two of the individual weights deviated from the average 
weight by more than 7.5% for 300 mg tablets and none by more than double that 
percentage.  
D.Friability test:  
20 previously weighed tablets were placed in the friability apparatus, which 
was given 100 revolutions and the tablets were reweighed. The percentage friability 
was calculated by using the following formula,  
Percentage friability = initial weight-final weight /initial weight × 100.  
 
Fig.No:13.Friability Apparatus 
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E.Drug content:  
20 tablets of each formulation were weighed and powdered. The quantity of 
powder equivalent to 100 mg of Zanamivir was transferred in to a 100 ml volumetric 
flask and the volume adjusted to 100ml with 0.1N HCl. Further 1ml of the above 
solution was diluted to 100 ml with 0.1N HCl and check the absorbance of the 
resulting solution was observed at 216nm.  
F.In-vitro Buoyancy studies:  
The in-vitro buoyancy was determined by floating lag time, and total floating 
time. The tablets were placed in a 100ml beaker containing 0.1N HCl. The time 
required for the tablet to rise to the surface and float was determined as floating lag 
time (FLT) and the duration of the time the tablet constantly floats on the dissolution 
medium was noted as the Total Floating Time respectively (TFT). 
G.Swelling Index Studies: 
            The swelling behavior of a dosage unit wasmeasured by studying its weight 
gain. The swelling indexof tablets was determined by placing the tablets in thebasket 
of dissolution apparatus using dissolution mediumas 0.1N HCl at 37±0.5°C. After 1, 4 
and 6h each dissolution basket containing tablet waswithdrawn, blotted with tissue 
paper to remove theexcess water and weighed on the analytical balance(Schimdzu, 
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AX 120). The experiment was performedin triplicate for each time point. Swelling 
index wascalculated by using the following formula 
 (Wet weight of tablet – Dry weight of tablet) 
Swelling index = 
                                Dry weight of tablet. 
 
H. In-Vitro Dissolution Studies of Tablets: 
Dissolution parameters:  
Apparatus   -- USP-II, Paddle Method 
Dissolution Medium   --  0.1 N HCl 
RPM     -- 50  
Sampling intervals (hrs) -- 0.5,1,2,3,4,5,6,8 and 10  
Temperature   -- 37 + 0.5°C 
Dissolution Study40: 
900ml 0f 0.1 HCl was placed in the vessel and the USP apparatus –II (Paddle 
Method) was assembled. The medium was allowed to equilibrate to temp of 37 + 
0.5°C. Tablet was placed in the vessel and the vessel was covered, the apparatus was 
operated for 10 hours at 50 rpm. At definite time intervals, 5 ml of the fluid was 
withdrawn; filtered and again 5ml of the fresh buffer was replaced. Suitable dilutions 
were done with the dissolution fluid and the samples were analyzed 
spectrophotometrically at 216 nm. 
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Fig.No:14.Dissolution Apparatus 
Release Kinetics : 
 The analysis of drug release mechanism from a pharmaceutical dosage form is 
an important but complicated process and is practically evident in the case of matrix 
systems. As a model-dependent approach, the dissolution data was fitted to four 
popular release models such as zero-order, first-order, diffusion and Peppa’s- 
Korsemeyer equations, which have been described in the literature. The order of drug 
release from matrix systems was described by using zero order kinetics or first orders 
kinetics. The mechanism of drug release from the matrix systems was studied by 
using Higuchi equation and Peppa’s- Korsemeyer equation. The results are given in 
Table . 
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Zero Order Release Kinetics: 
 It defines a linear relationship between the fractions of drug released versus 
time.                                                                      
Q = kot 
Where, Q is the fraction of drug released at time t and ko is the zero order release rate 
constant. 
A plot of the fraction of drug released against time will be linear if the release 
obeys zero order release kinetics. 
First Order Release Kinetics: 
 Wagner assuming that the exposed surface area of a tablet decreased 
exponentially with time during dissolution process suggested that drug release from 
most of the slow release tablets could be described adequately by apparent first-order 
kinetics. The equation that describes first order kinetics is 
In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and k1 is the first order release rate 
constant. 
 Thus, a plot of the logarithm of the fraction of drug remained against time will 
be linear if the release obeys first order release kinetics. 
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Higuchi equation: 
 It defines a linear dependence of the active fraction released per unit of surface 
(Q) on the square root of time. 
                                                         Q=K2t½    
Where, K2 is the release rate constant. 
A plot of the fraction of drug released against square root of time will be linear 
if the release obeys Higuchi equation. This equation describes drug release as a 
diffusion process based on the Fick’s law, square root time dependant. 
Koresmeyer Peppas 
 In order to define a model, which would represent a better fit for the 
formulation, dissolution data was further analyzed by Peppa’s and Korsemeyer 
equation (Power Law). 
Mt/M = K.tn 
Where, Mt is the amount of drug released at time t and M is the amount 
released at time , thus the Mt/Mis the fraction of drug released at time t, k is the 
kinetic constant and n is the diffusion exponent. To characterize the mechanism for 
both solvent penetration and drug release n can be used as abstracted in Table. A plot 
between log of Mt/M against log of time will be linear if the release obeys Peppa’s 
and Korsemeyer equation and the slope of this plot represents “n” value.   
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Table.No:11.Diffusion exponent and solute release mechanism for                  
cylindrical shape 
 
6.7.Stability studies 
Stability studies were carried out according to ICH guidelines by 
exposing the. Formulations f5 in their final packing mode to the temperature 
40±2°C and relative humidity 75±5 % in programmable environmental test 
chamber (CHM-10S, Remi Instruments Ltd., Mumbai, India). Aliquot were 
withdrawn at 30 and 60 days and analyzed for change in drug content and in-
vitro dissolution profile 
Selected Formulation was subjected to stability studies as per ICH guidelines. 
Following conditions were used for Stability Testing: 
Diffusion Exponent  Overall solute diffusion mechanism 
0.45 Fickian diffusion  
0.45<n<0.89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n>0.89 Super Case II transport 
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1. 21˚C/45% RH analyzed every month for period of three months. 
2. 25˚C/60% RH analyzed every month for period of three months. 
3. 30˚C/70% RH analyzed every month for period of three months. 
                                     
                 
 
 
 
 
 
Fig.No:15.Stability Chamber 
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7. RESULTS AND DISCUSSION 
7.1.STANDARD GRAPH OF ZANAMIVIR: 
Table.No:12.  Standard graph of ZANAMIVIR 
Conc (µg/ml) Absorbance 
16 0.421 
18 0.472 
20 0.520 
22 0.562 
24 0.612 
 
 
   Fig.No:16.Standard calibration curve of Zanamivir 
y = 0.0256x + 0.0041 
R² = 0.9992 
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7.2.FT-IR STUDIES:  
The FTIR spectra of the drug (alone), polymer (alone) and the drug-polymer 
(mixture) were recorded by the potassium bromide pellet method. From the infrared 
spectra it is clearly evident that there were no drug-polymer interactions of the drug. 
 
Fig.No:17. FT-IR Spectra of Zanamivir 
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Fig.No:18.FT-IR Spectra of Zanamivir final formulation 
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7.3. PREFORMULATION STUDIES OF POWDERED BLEND 
Preformulation studies of powdered blend parameters like bulk density, tapped 
density, compressibility index, Hausner’s ratio and angle of repose as shown in the 
table below. 
Table.No:13.Pre-compression parameters for formulation batches 
Formulation 
code 
Bulk 
density 
(gm/mL) 
Tapped 
density 
(gm/mL) 
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle of 
repose () 
F1 0.721±0.04
5 
0.87± 0.01 17.126±0.6 1.206±0.06 26.620.21 
F2 0.710±0.04
3 
0.873±0.04 19.714±0.7 1.251±0.04 27.460.11 
F3 0.41±0.045 0.483±0.5 15.113±0.8 1.178±0.08 28.320.31 
F4 0.45±0.045 0.52 ± 0.09 15.60±0.2 1.15±0.02 28.060.31 
F5 0.45±0.045 0.50 ± 0.07 12.23±0.6 1.11±0.04 27.580.15 
F6 0.44±0.044 0.50 ± 0.09 12.58±0.8 1.13±0.08 28.440.11 
 
(n = 3) 
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POST COMPRESSION PARAMETERS 
The results of the weight variation, hardness, friability, drug content, 
Buoyancy lag time and Total floating time of the Tablets are given in table 
In-vitro Buoyancy studies: 
 In-vitro buoyancy of the tablets from each formulation (F1 to F6) was 
evaluated and the results are mentioned in Table 14. Where, the highest and lowest 
floating lag time (FLT) was observed with the formulation F1 and F6 respectively. 
The concentration of the natural polymers increases the floating lag time also 
increases and total floating time observed for all the formulations  was >10 hours. 
 
At initial time 
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After 20 Sec 
 
 
After 10 hrs 
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Table.No:14.Post compression evaluation parameters of ZANAMIVIR              
floating Tablets 
Formulation 
No. 
Avg. Weight 
(Mean± S.D) 
(n=20) 
Hardness 
(kg/cm2) 
(n=3) 
Friability 
(Mean±S.D) 
(n=6) 
% Drug 
content 
(mg) 
Buoyancy 
Lag time 
(min) 
Total 
floating 
Time(hrs) 
F1 353±0.6 7.2±0.4 0.546 98±0.7 26        5 
F2 350±0.9 7.5±0.4 0.612 99±0.5 18 6 
F3 347±0.3 7.4±0.6 0.527 98±0.6 20 10 
F4 351±0.4 7.6±0.1 0.511 99±0.6 30 8 
F5 346±0.8 7.6±0.6 0.525 99±0.6 61 8 
F6 354±0.8 7.3±0.4 0.555 98±0.5 35 10 
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7.4. Swelling index studies 
Table.No:15.Swelling index studies of ZANAMIVIR floating Tablets 
 
Time(hr) 
Swelling index ratio (%) 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
2 32 35 42 46 50 55 
4 46 48 50 51 58 60 
6 52 55 58 65 67 72 
8 49 50 52 54 59 64 
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7.5. Dissolution studies 
Table.No:16.Dissolution Data Of ZANAMIVIR Floating Tablets 
TIME 
(hr) 
% of Drug Release 
F1 F2 F3 F4 F5 F6 
1 18.8 14.3 11.3 16.5 12.4 9.2 
2 39.9 22.2 21.4 29.8 30.8 19.3 
3 52.3 37.6 32.8 41.9 42.3 26.9 
4 76.9 46.8 46.1 50.2 49.4 38.2 
5 92.8 76.8 58.4 61.1 60.3 46.8 
6 92.8 96.3 69.5 72.7 76.4 58.3 
8 92.8 96.3 79.9 96.3 90.2 71.4 
10 92.8 96.3 90.4 96.3 97.4 84.9 
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Fig.No:19.Dissolution profile of Zanamivir Floating Tablets 
The % Cumulative drug release of all the formulations F1, F2, F4 was not able 
to sustain the drug release for 10 hrs. F3 and F6 formulations showed good integrity 
for 10 hrs. F4 formulation was optimised based on the floating behaviour. The 
optimized formulation F5 showed  % drug release of 97.4% for 10 hrs which shows 
greater release compare to all other formulation. 
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Fig 20 : Dissolution profile of Zanamivir Floating Tablets of  F1 
0 
14.3 
22.2 
37.6 
46.8 
76.8 
96.3 
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9 10
cu
m
u
la
ti
ve
 %
 d
ru
g
 r
e
le
a
se
 
time in hrs 
Fig 21 : Dissolution profile of Zanamivir Floating Tablets of F2 
RESULTS AND DISCUSSION 
 
Dept. of Pharmaceutics        88  JKKMMRF College of Pharmacy 
 
 
 
0 
11.3 
21.4 
32.8 
46.1 
58.4 
69.5 
79.9 
90.4 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 8 10
cu
m
u
la
ti
ve
 %
 d
ru
g
 r
e
le
a
se
 
time in hrs 
Fig 22 : Dissolution profile of Zanamivir Floating Tablets of F3 
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Fig 23 : Dissolution profile of Zanamivir Floating Tablets of F4 
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Fig 24 : Dissolution profile of Zanamivir Floating Tablets of F5 
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Fig 25 : Dissolution profile of Zanamivir Floating Tablets of F6 
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7.6.KINETIC MODELLING AND MECHANISM OF DRUG RELEASE: 
The results of kinetic equations applied to dissolution profiles of optimized batch 
F5 were determined as follows. 
Table.No:17. Kinetic values obtained from different plots of F5 formulation 
  ZERO 
   ORDER 
FIRST 
    ORDER 
HIGUCHI 
  ORDER 
PEPPAS 
ORDER 
  % CDR Vs 
T 
Log % 
Remain Vs 
T 
%CDR Vs 
√T 
Log C Vs 
Log T 
Slope 10.0480 -0.1512 33.7231 1.4567 
Intercept 7.4806 2.1695 -12.0120 0.7304 
Correlation 0.9823 -0.9609 0.9772 0.8513 
R 2 0.9649 0.9235 0.9549 0.7247 
 
The release kinetics of all the dosage forms were calculated using zero-order, 
first-order, higuchi and krosemeyer-peppas. Optimized formulation was found to 
follow higuchi release kinetics. The optimized formulation F5 was found to exhibit 
zero–order which shows that the diffusion along with dissolution of the drug from the 
tablet. 
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                            Fig.No:26. First order release model for F5 formulation 
 
 
                       Fig.No:27. Zero order release model for F5 formulation 
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                            Fig.No:28. Peppas release model for F5 formulation 
 
 
Fig.No:29. Higuchi release model for F5 formulation 
y = 1.4568x + 0.7305 
R² = 0.7248 
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7.7. ZANAMIVIR FLOATING TABLETS 
Table.No:18.Stability data of optimised formulation F5 
 
(mean ± SD) (n=3) 
S.  
No 
Time 
points 
(hr) 
Initial 
Cumulative % Drug Release 
25˚C/60%RH 40˚C/75%RH 
1st Month 3rd  Month 1stMonth 3rdMonth 
1 1 12.4 12.2 11.7 11.2 10.7 
2 2 30.8 30.4 30.1 29.4 29.1 
3 3 42.3 42.1 41.8 39.6 39.2 
4 4 49.4 49.0 48.6 47.8 47.4 
5 5 60.3 58.3 59.4 59.1 58.6 
6 6 76.4 76.1 75.5 75.1 74.9 
7 8 90.2 89.8 89.2 88.7 88.1 
8 10 97.4 97.1 96.5 96.1 95.8 
9 Assay 99.5 99.2 99.1 98.7 98.5 
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The optimized formula was kept for stability studies. The cumulative % Drug 
release kinetics was used to predict the stability of the preparation. The mean values 
of these parameters were compared with that obtained on 1st month as described in 
table.  The results are shown in Table.No.18. There was less significant change in % 
entrapment efficiency at storage temperatures after 3 month of  production which 
indicates the stability of preparation. 
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8. SUMMARY AND CONCLUSION 
 Gastro retentive dosage form using Guar gum was prepared to develop a floating 
tablet of Zanamivir that could retain in the stomach for longer periods of time 
delivering the drug to the site of action, i.e., stomach. 
 The pre-compression parameters of all formulations showed good flow properties 
and these can be used for tablet manufacture. 
 The post-compression parameters of all formulations were determined and the 
values were found to be satisfactory.  
 From the drug content and in-vitro dissolution studies of the formulations, it was 
concluded that the formulation F5 i.e. the formulation containing Guargum, PVP,  
Sodium bicarbonate, micro crystalline cellulose and Magnesium stearate is the 
best formulation. 
 The % Cumulative drug release of all the formulations F1, F2, F4 was not able to 
sustain the drug release for 10 hrs. F3 and F6 formulations showed good integrity 
for 10 hrs. F4 formulation was optimised based on the floating behaviour. The 
optimized formulation F5 showed a %drug release of 97.4% for 10 hrs which 
shows greater release compare to all other formulation. 
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As a result of this study it may be concluded that the floating tablets using a 
guar gum in optimized concentration can be used to increase the GRT of the 
dissolution fluid in the stomach to deliver the drug in a controlled manner. The 
concept of formulating floating tablets of Zanamivir offers a suitable and practical 
approach in serving desired objectives of gastro retentive floating tablets. 
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